The present invention concerns the compounds having the formula ##STR00001## N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R.sub.1 and R.sub.8 each are H, optionally substituted C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.3-7cycloalkyl, aryl, Het.sup.1, Het.sup.2; R.sub.1 may also be a radical of formula (R.sub.11aR.sub.11b)NC(R.sub.10aR.sub.10b)CR.sub.9--; t is 0, 1 or 2; R.sub.2 is H or C.sub.1-6alkyl; L is --C(.dbd.O)--, --O--C(.dbd.O)--, --NR.sub.8--C(.dbd.O)--, --O--C.sub.1-6alkanediyl-C(.dbd.O)--, --NR.sub.8--C.sub.1-6alkanediyl-C(.dbd.O)--, --S(.dbd.O).sub.2--, --O--S(.dbd.O).sub.2--, --NR.sub.8--S(.dbd.O).sub.2; R.sub.3 is C.sub.1-6alkyl, aryl, C.sub.3-7cycloalkyl, C.sub.3-7cycloalkylC.sub.1-4alkyl, or arylC.sub.1-4alkyl; R.sub.4 is H, C.sub.1-4alkylOC(.dbd.O), carboxyl, aminoC(.dbd.O), mono- or di(C.sub.1-4alkyl)aminoC(.dbd.O), C.sub.3-7cycloalkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl or optionally substituted C.sub.1-6alkyl; A is C.sub.1-6alkanediyl, --C(.dbd.O)--, --C(.dbd.S)--, --S(.dbd.O).sub.2--, C.sub.1-6alkanediyl-C(.dbd.O)--, C.sub.1-6alkanediyl-C(.dbd.S)-- or C.sub.1-6alkanediyl-S(.dbd.O).sub.2--; R.sub.5 is H, OH, C.sub.1-6alkyl, Het.sup.1C.sub.1-6alkyl, Het.sup.2C.sub.1-6alkyl, optionally substituted aminoC.sub.1-6alkyl; R.sub.6 is C.sub.1-6alkylO, Het.sup.1, Het.sup.1O, Het.sup.2, Het.sup.2O, aryl, arylO, C.sub.1-6alkyloxycarbonylamino or amino; and in case -A- is other than C.sub.1-6alkanediyl then R.sub.6 may also be C.sub.1-6alkyl, Het.sup.1C.sub.1-4alkyl, Het.sup.1OC.sub.1-4alkyl, Het.sup.2C.sub.1-4alkyl, Het.sup.2OC.sub.1-4alkyl, arylC.sub.1-4alkyl, arylOC.sub.1-4alkyl or aminoC.sub.1-4alkyl; whereby each of the amino groups in the definition of R.sub.6 may optionally be substituted; -A-R.sub.6 is hydroxyC.sub.1-6alkyl; R.sub.5 and -A-R.sub.6 taken together with the nitrogen atom to which they are attached may also form Het.sup.1 or Het.sup.2. It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.

 
Web www.patentalert.com

< Substituted thieno[3,2-D]pyrimidines as HIV inhibitors

> IGG1 monoclonal antibody with anti-HIV neutralizing activity

> Polynucleotide encoding an il-29 polypeptide

~ 00546